Improving our knowledge of how baseline measures of tau, neuroinflammation, and brain atrophy predict cognitive decline in Alzheimer’s disease may inform future cost-effectiveness of studies in large and epidemiologically representative cohorts of patients. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.